Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Investors keep the faith in cancer liquid biopsies

Despite slow uptake in the clinic, liquid biopsy tests incorporating methylation and other signatures are showing increasingly compelling data for non-invasive detection of cancer.
  1. Cormac Sheridan

    1. Dublin, Ireland

    View author publications

    You can also search for this author in PubMed  Google Scholar

Liquid-biopsy platforms, which have long faced considerable scepticism as to their utility in clinical practice, are attracting a new bout of intense investor interest.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Biotechnology 37, 972-974 (2019)

doi: https://doi.org/10.1038/d41587-019-00022-7

Updates & Corrections

  • Correction 03 June 2020: An earlier version of this article omitted mention in Table 1 of Guardant360’s FDA breakthrough device designation 15 February 2018

  • Correction 03 June 2020: The Table 1 incorrectly stated that MirXes’ products were at research stage when GastroClear has been available in Singapore since its approval on 9 May 2019 by the Singapore by the Health Sciences Authority.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links